Human papillomavirus (HPV) infection causes cervical cancer and genital warts. Young
women (1106) were randomized to receive one of three formulations of a quadrivalent HPV …

Abstract Background. The quadrivalent (types 6, 11, 16, and 18) human papillomavirus
(HPV) L1 virus-like-particle vaccine was 95%–100% effective in preventing cervical and …

Human papillomavirus (HPV) infection can cause genital warts and cervical cancer. HPV
types 6 and 11 cause> 90% of genital wart cases; HPV16 and 18 cause 70% of cervical …

In this study, we evaluated the potency of a human papillomavirus (HPV) virus-like particle
(VLP)-based vaccine at generating HPV type 11 (HPV-11)-specific cellular and humoral …

Two candidate vaccines to prevent infection with human papillomavirus (HPV) Types 11 and
16 were studied in similar double-blind, placebo-controlled, dose-escalation trials. L1 virus …

Two HPV virus-like particle (VLP) vaccines, HPV-16/18 (GlaxoSmithKline, Cervarix®) and
HPV-6/11/16/18 (Merck, Gardasil®), are currently licensed in the United States. Given the …

A post hoc analysis was performed using combined data from two Phase I tolerability/
immunogenicity studies of monovalent human papillomavirus type 11 (HPV11) or HPV16 L1 …

Abstract Background. A quadrivalent (types 6, 11, 16, and 18) human papillomavirus (HPV)
L1 virus-like-particle (VLP) vaccine has been shown to be 95%–100% effective in …

Background We evaluated the impact of a quadrivalent human papillomavirus (HPV)
vaccine on infection and cervical disease related to 10 nonvaccine HPV types (31, 33, 35 …

In this observer-blind study (NCT00423046), women (N= 1,106), stratified by age (18–26, 27–
35, 36–45 years), were randomized (1: 1) to receive the HPV-16/18 vaccine (Cervarix® …